mGluR1 negative allosteric modulators: An alternative metabotropic approach for the treatment of schizophrenia

Milestones in Drug Therapy

Volumn , Issue , 2010, Pages 117-131

  Ohta, Hisashi ^a   Kawamoto, Hiroshi ^b   Suzuki, Gentaroh ^b  

^a Sato Pharmaceutical Co Ltd   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

(3 ETHYL 2 METHYLQUINOLIN 6 YL)(4 METHOXYCYCLOHEXYL)METHANONE METHANSULFONATE; (3,4 DIHYDRO 2H PYRANO[2,3]B QUINOLIN 7 YL)(CIS 4 METHOXYCYCLOHEXYL)METHANONE; 2 CYCLOPROPYL 5 [1 (2 FLUORO 3 PYRIDINYL) 5 METHYL 1H 1,2,3 TRIAZOL 4 YL] 2,3 DIHYDRO 1H ISOINDOL 1 ONE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 1,3 THIAZOL 4YL)ETHYNYL]PYRIDINE; 3,5 DIHYDROXYPHENYLARGININE; 4 [1 (2 FLUOROPYRIDIN 3 YL) 5 METHY 1H 1,2,3 TRIAZOL 4 YL] N ISOPROPYL N METHYL 3,6 DIHYDROPYRIDINE 1(2H) CARBOXAMIDE; 4 AMINO 2 OXABICYCLO[3.1.0]HEXANE 4,6 DICARBOXYLIC ACID; 4 CARBOXY 2 METHYLPHENYLGLYCINE; 6A NAPHTALAN 2YLMETHYL 5 METHYLIDENHEXAHYDROCYCLOPENTAL[C]FURAN 1 ON; 7 (HYDROXYIMINO)CYCLOPROPA[B]CHROMEN 1A CARBOXYLATE ETHYL ESTER; BAY 36 7620; CLOZAPINE; DIZOCILPINE; DOPAMINE RECEPTOR STIMULATING AGENT; HALOPERIDOL; JNJ 16259685; KETAMINE; METABOTROPIC RECEPTOR 1; METABOTROPIC RECEPTOR 1 ANTAGONIST; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 2 ANTAGONIST; METABOTROPIC RECEPTOR 3; METABOTROPIC RECEPTOR 3 ANTAGONIST; METABOTROPIC RECEPTOR ANTAGONIST; METHAMPHETAMINE; N CYCLOHEPTYL 6 [[(TETRAHYDROFURAN 2 YLMETHYL)AMINO]METHYL]THIENO[2,3 D]PYRIMIDIN 4 AMINE; PROTEIN C FOS; UNCLASSIFIED DRUG; YM 230888;

ARTICLE; DISEASE MODEL; DRUG EFFECT; DRUG MEGADOSE; HUMAN; LOCOMOTION; NONHUMAN; PREPULSE INHIBITION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SCHIZOPHRENIA; SOCIAL INTERACTION;

EID: 79953698476     PISSN: None     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-3-0346-0241-9_7     Document Type: Article

References (49)

1. Andreasen NC (2000) Schizophrenia: the fundamental questions. Brain Res Rev 31:106-112
2. Laborit H (1949) Sur l'utilization de certain agents pharmacodynamiques a action neurovegetative en periode per- and post-operatioire. Acta Chir Belg 87:485-492
3. Carlsson A, Lindquist M(1963) Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine in mouse brain. Acta Pharmacol Toxicol 20:140-144
4. Sovner R, DiMascio A (1978) Extrapyramdal syndrome and other neurological side effects of psychotropic drugs. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 1021-1032
5. Baldessarini RJ, Tarsy D (1978) Tardive dyskinesia. In: Lipton MA, DiMascio A, Killam KF (eds) Psychopharmacology: a generation of progress. Raven Press, New York, pp 993-1004
6. Kane J, Honigfeld G, Singer J, Meltzer H (1988) Clozapine for the treatment-resistant schizophrenic A double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789-796
7. Sur C, Mallorga PJ, Wittmann M, Jacobson MA, Pascarella D, Williams JB, Brandish PE, Pettibone DJ, Scolnick EM, Conn PJ (2003) N-desmethylclozapine, an allosteric agonist at muscarinic 1 receptor, potentiates N-methyl-D-aspartate receptor activity. Proc Natl Acad Sci USA 100:13674-13679
8. Javitt DC, Zukin SR (1991) Recent advance in the phencyclidine model of schizophrenia. Am J Psychiatry 148:1301-1308
9. Lahti AC, Koffel B, LaPorte D, Tamminga CA (1995) Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13:9-19
10. Moghaddam B, Adams BW (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281:1349-1352
11. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA et al (2007) Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized phase 2 clinical trial. Nat Med 13:1102-1107
12. De Blasi A, Conn PJ, Pin JP, Nicoletti F (2001) Molecular determinants of metabotropic glutamate receptor signaling. Trends Pharmacol Sci 22:114-120
13. Spooren W, Ballard T, Gasparini F, Amalric M, Mutel V, Schreiber R (2003) Insight into the function of group I and group II metabotropic glutamate (mGlu) receptors: behavioral characterization and implications for the treatment of CNS disorders. Behav Pharmacol 14:257-277
14. Shigemoto R, Nakanishi S, Mizuno N (1992) Distribution of the mRNA for a metabotropic glutamate receptor (mGluR1) in the central nervous system: an in situ hybridization study in adult and developing rat. J Comp Neurol 322:121-135
15. Nakajima Y, Iwakabe H, Akazawa C, Nawa H, Shigemoto R, Mizuno N, Nakanishi S (1993) Molecular characterization of a novel retinal metabotropic glutamate receptor mGluR6 with a high agonist selectivity for L-2-amino-4-phosphonobutyrate. J Biol Chem 268: 11868-11873
16. Klodzińska A, Chojnacka-Wójcik E, Palucha A, Brański P, Popik P, Pilc A (1999) Potential anti-anxiety, anti-addictive effects of LY 354740, a selective group II glutamate metabotropic receptors agonist in animal models. Neuropharmacology 38:1831-1839
17. Cartmell J, Monn JA, Schoepp DD (2000) The mGlu(2/3) receptor agonist LY379268 selectively blocks amphetamine ambulations and rearing. Eur J Pharmacol 400:221-224
18. Grillon C, Cordova J, Levine LR, Morgan CA III (2003) Anxiolytic effects of a novel group II metabotropic glutamate receptor agonist (LY354740) in the fear-potentiated startle paradigm in humans. Psychopharmacology (Berl) 168:446-454
19. Simmons RM, Webster AA, Kalra AB, Iyengar S (2002) Group II mGluR receptor agonists are effective in persistent and neuropathic pain models in rats. Pharmacol Biochem Behav 73:419-427
20. Fundytus ME (2001) Glutamate receptors and nociception. CNS Drugs 15:29-58
21. Javitt DC (2004) Glutamate as a therapeutic target in psychiatric disorders. Mol Psychiatry 9:984-997
22. Grauer SM, Marquis KL (1999) Intracerebral administration of metabotropic glutamate receptor agonists disrupts prepulse inhibition of acoustic startle in Sprague-Dawley rats. Psychopharmacology (Berl) 141:405-412
23. De Vry J, Horváth E, Schreiber R (2001) Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu1 receptor antagonist BAY 36-7620. Eur J Pharmacol 428:203-214
24. Lavreysen H, Pereira SN, Leysen JE, Langlois X, Lesage ASJ (2004) Metabotropic glutamate 1 receptor distribution and occupancy in the rat brain: a quantitative autoradiographic study using [3H]R214127. Neuropharmacology 46:609-619
25. Lavreysen H, Wouters R, Bischoff F, Nóbrega Pereira S, Langlois X, Blokland S, Somers M, Dillen L, Lesage ASJ (2004) JNJ16259685, a highly potent, selective and systemically active mGlu1 receptor antagonist. Neuropharmacology 47:961-972
26. Suzuki G, Kimura T, Satow A, Kaneko N, Fukuda J, Hikichi H, Sakai N, Maehara S, Kawagoe-Takaki H, Hata M et al (2007) Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-Fluoropyridin-3-yl)-5-methyl-1H-1, 2, 3-triazol-4-yl]-N-isopropyl-N-methyl-3, 6- dihydropyridine-1 (2H)-carboxamide (FTIDC). J Pharmacol Exp Ther 321:1144-1153
27. Satow A, Maehara S, Ise S, Hikichi H, Fukushima M, Suzuki G, Kimura T, Tanaka T, Ito S, Kawamoto H et al (2008) Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric mGluR1 antagonist, FTIDC, (4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3- triazol-4-yl]-N-isopropyl-N-methyl-3,6-dihydropyridine-1(2H)-carboxamide ). J Pharmacol Exp Ther 326:577-586
28. Satow A, Suzuki G, Maehara S, Hikichi H, Murai T, Murai T, Kawagoe-Takaki H, Hata M, Ito S, Ozaki S et al (2009) Unique antipsychotic activities of the selective metabotropic glutamate receptor 1 allosteric antagonist 2-cyclopropyl-5-[1-(2-fluoro-3-pyridinyl)-5-methyl-1H-1, 2, 3-triazol-4-yl]-2, 3-dihydro-1H-isoindol-1-one. J Pharmacol Exp Ther 330:179-190
29. Suzuki G, Kawagoe-Takaki H, Inoue T, Kimura T, Hikichi H, Murai T, Satow A, Hata M, Maehara S, Ito S et al (2009) Correlation of receptor occupancy of metabotropic glutamate receptor subtype 1 (mGluR1) in mouse brain with in vivo activity of allosteric mGluR1 antagonists. J Pharmacol Sci 110:315-325
30. Hikichi H, Iwahori Y, Murai T, Maehara S, Satow A, Ohta H (2008) Face-washing behavior induced by the group I metabotropic glutamate receptor agonist (S)-3, 5-DHPG in mice is mediated by mGlu1 receptor. Eur J Pharmacol 586:212-216
31. Renoldi G, Calcagno E, Borsini F, Invernizzi RW (2006) Stimulation of group I mGlu receptors in the ventrotegmental area enhances extracellular dopamine in the rat medial prefrontal cortex. J Neurochem 100:1658-1666
32. Greenslade RG, Mitchell SN (2004) Selective action of (-)-2-oxa-4-aminobicyclo[3.1.0] hexane-4, 6-dicarboxylate (LY379268), a group II metabotropic glutamate receptor agonist, on basal and phencyclidine-induced dopamine release in the nucleus accumbens shell. Neuropharmacology 47:1-8
33. Braff DL, Grillon C, Geyer MA (1992) Gating and habituation of the startle reflex in schizophrenic patients. Arch Gen Psychiatry 49:206-215
34. Carlsson A, Hansson LO, Waters N, Carlsson ML (1997) Neurotransmitter aberrations in schizophrenia: new perspectives and therapeutic implications. Life Sci 61:75-94
35. Brody SA, Conquet F, Geyer MA (2003) Disruption of prepulse inhibition in mice lacking mGluR1. Eur J Neurosci 18:3361-3366
36. Aiba A, Kano M, Chen C, Stanton ME, Fox GD, Herrup K, Zwingman TA, Tonegawa S (1994) Deficient cerebellar long-term depression and impaired motor learning in mGluR1 mutant mice. Cell 79:377-388
37. Kinney GG, Burno M, Campbell UC, Hernandez LM, Rodriguez D, Bristow LJ, Conn PJ (2003) Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents. J Pharmacol Exp Ther 306:116-123
38. Pietraszek M, Gravius A, Scḧafer D, Weil T, Trifanova D, Danysz W(2005) mGluR5, but not mGluR1, antagonist modifies MK-801-induced locomotor activity and deficit of prepulse inhibition. Neuropharmacology 49:73-85
39. Moghaddam B, Adams B, Verma A, Daly D (1997) Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17:2921-2922
40. Schreiber R, Lowe D, Voerste A, De Vry J (2000) LY354740 affects startle responding but not sensorimotor gating or discriminative effects of phencyclidine. Eur J Pharmacol 388: R3-R4
41. Musante V, Neri E, Feligioni M, Puliti A, Pedrazzi M, Conti V, Usai C, Diaspro A, Ravazzolo R, Henley JM, Battaglia G, Pittaluga A (2008) Presynaptic mGlu1 and mGlu5 autoreceptors facilitate glutamate exocytosis from mouse cortical nerve endings. Neuropharmacology 55:474-482
42. Melendez RI, Vuthiganon J, Kalivas PW (2005) Regulation of extracellular glutamate in the prefrontal cortex: focus on the cystine glutamate exchanger and group I metabotropic glutamate receptors. J Pharmacol Exp Ther 314:139-147
43. Paz RD, Tardito S, Atzori M, Tseng KY (2008) Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology. Eur Neuropsychopharmacol 18:773-786
44. Robertson GS, Matsumura H, Fibiger HC (1994) Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J Pharmacol Exp Ther 271:1058-1066
45. Sumner BE, Cruise LA, Slattery DA, Hill DR, Shahid M, Henry B (2004) Testing the validity of c-fos expression profiling to aid the therapeutic classification of psychoactive drugs. Psychopharmacology (Berl) 171:306-321
46. Sillevis Smitt P, Kinoshita A, De Leeuw B, Moll W, Coesmans M, Jaarsma D, Henzen-Logmans S, Vecht C, De Zeeuw C et al (2000) Paraneoplastic cerebellar ataxia due to autoantibodies against a glutamate receptor. N Engl J Med 342:21-27
47. Steckler T, Oliveira AF, Van Dyck C, Van Craenendonck H, Mateus AM, Langlois X, Lesage ASJ, Prickaerts J (2005) Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav Brain Res 164:52-60
48. Murai T, Okuda S, Tanaka T, Ohta H (2007) Characteristics of object location memory in mice: behavioral and pharmacological studies. Physiol Behav 90:116-124
49. Meltzer HY, McGurk SR (1999) The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr Bull 25:233-255